Cannabinoid Modulation of Cortical Adrenergic Receptors and Transporters

Overview

Journal J Neurosci Res

Specialty Neurology

Date 2009 Jun 18

PMID 19533736

Citations 16

Authors

B A S Reyes

J C Rosario

P M T Piana

E J Van Bockstaele

Affiliations

Soon will be listed here.

Abstract

We previously reported that administration of the synthetic cannabinoid agonist WIN 55,212-2 causes an increase in norepinephrine (NE) efflux in the frontal cortex (FC). The present study examined the expression levels of alpha2- and beta1-adrenergic receptors (ARs) as well as the norepinephrine transporter (NET) in the FC of rats following exposure to WIN 55,212-2. Rats received systemic injection of WIN 55,212-2 (3 mg/kg) acutely or for 7 days. Another group of rats received repeated WIN 55,212-2 treatment followed by a period of abstinence. Control rats received vehicle injections. Rats were euthanized 30 min after the last WIN 55,212-2 injection, the FC was microdissected, and protein extracts were probed for alpha2-AR, beta1-AR, and NET. Results showed that beta1-AR expression was significantly decreased following repeated WIN 55,212-2 treatment but significantly increased following a period of abstinence. alpha2-AR expression showed no significant change in all groups examined. NET expression was significantly decreased following acute WIN 55,212-2 treatment, with no changes following chronic administration or a period of abstinence. Alterations in NET may arise from modulation of cannabinoid receptors (CB1) that are localized to noradrenergic axon terminals as we demonstrate colocalization of CB1 receptor and NET in the same cortical axonal processes. The present findings support significant alterations in adrenergic receptor and NET expression in the FC after WIN 55,212 exposure that may underlie the reported changes in attention, cognition, and anxiety commonly observed after cannabinoid exposure.

Citing Articles

Formoterol dynamically alters endocannabinoid tone in the periaqueductal gray inducing headache.

Peterson I, Liktor-Busa E, Karlage K, Young S, Scholpa N, Schnellmann R J Headache Pain. 2024; 25(1):200.

PMID: 39563240 PMC: 11575070. DOI: 10.1186/s10194-024-01907-y.

Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Reyes B, Carvalho A, Szot P, Kalamarides D, Wang Q, Kirby L Exp Neurol. 2017; 292:179-192.

PMID: 28341460 PMC: 5454488. DOI: 10.1016/j.expneurol.2017.03.010.

The effects of synthetic cannabinoids on executive function.

Cohen K, Kapitany-Foveny M, Mama Y, Arieli M, Rosca P, Demetrovics Z Psychopharmacology (Berl). 2017; 234(7):1121-1134.

PMID: 28160034 DOI: 10.1007/s00213-017-4546-4.

Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males.

Wiers C, Shokri-Kojori E, Wong C, Abi-Dargham A, Demiral S, Tomasi D Neuropsychopharmacology. 2016; 41(10):2596-605.

PMID: 27156854 PMC: 4987858. DOI: 10.1038/npp.2016.67.

Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats.

Zhang H, Bi G, Li X, Li J, Qu H, Zhang S Neuropsychopharmacology. 2014; 40(4):1037-51.

PMID: 25374096 PMC: 4330519. DOI: 10.1038/npp.2014.297.

References

Ghrebi S, Rh Owen G, Brunette D . Triton X-100 pretreatment of LR-white thin sections improves immunofluorescence specificity and intensity. Microsc Res Tech. 2007; 70(7):555-62. DOI: 10.1002/jemt.20422. View

Malone D, Taylor D . Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol. 1999; 128(1):21-6. PMC: 1571599. DOI: 10.1038/sj.bjp.0702753. View

Pratt G, Bowery N . Repeated administration of desipramine and a GABAB receptor antagonist, CGP 36742, discretely up-regulates GABAB receptor binding sites in rat frontal cortex. Br J Pharmacol. 1993; 110(2):724-35. PMC: 2175914. DOI: 10.1111/j.1476-5381.1993.tb13872.x. View

Page M, Oropeza V, Van Bockstaele E . Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett. 2007; 431(1):1-5. PMC: 2701365. DOI: 10.1016/j.neulet.2007.11.009. View

Paxinos G, Watson C, Emson P . AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods. 1980; 3(2):129-49. DOI: 10.1016/0165-0270(80)90021-7. View

Lapiz M, Morilak D . Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience. 2005; 137(3):1039-49. DOI: 10.1016/j.neuroscience.2005.09.031. View

Arnsten A . Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007; 17 Suppl 1:i6-15. DOI: 10.1093/cercor/bhm033. View

Rudoy C, Reyes A, Van Bockstaele E . Evidence for beta1-adrenergic receptor involvement in amygdalar corticotropin-releasing factor gene expression: implications for cocaine withdrawal. Neuropsychopharmacology. 2008; 34(5):1135-48. PMC: 3660858. DOI: 10.1038/npp.2008.102. View

Oropeza V, Page M, Van Bockstaele E . Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 2005; 1046(1-2):45-54. DOI: 10.1016/j.brainres.2005.03.036. View

10.

Tanda G, Pontieri F, Frau R, Di Chiara G . Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci. 1998; 9(10):2077-85. DOI: 10.1111/j.1460-9568.1997.tb01375.x. View

11.

Tejani-Butt S, Pare W, Yang J . Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats. Brain Res. 1994; 649(1-2):27-35. DOI: 10.1016/0006-8993(94)91045-6. View

12.

Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa G . Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002; 948(1-2):155-8. DOI: 10.1016/s0006-8993(02)03055-x. View

13.

Arnsten A . Through the looking glass: differential noradenergic modulation of prefrontal cortical function. Neural Plast. 2000; 7(1-2):133-46. PMC: 2565372. DOI: 10.1155/NP.2000.133. View

14.

Verrico C, Jentsch J, Dazzi L, Roth R . Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse. 2003; 48(4):178-83. DOI: 10.1002/syn.10202. View

15.

Bonisch H, Bruss M . The noradrenaline transporter of the neuronal plasma membrane. Ann N Y Acad Sci. 1994; 733:193-202. DOI: 10.1111/j.1749-6632.1994.tb17269.x. View

16.

Wenzel-Seifert K, Liu H, Seifert R . Similarities and differences in the coupling of human beta1- and beta2-adrenoceptors to Gs(alpha) splice variants. Biochem Pharmacol. 2002; 64(1):9-20. DOI: 10.1016/s0006-2952(02)00924-3. View

17.

Ranganathan M, DSouza D . The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006; 188(4):425-44. DOI: 10.1007/s00213-006-0508-y. View

18.

Bymaster F, Katner J, Nelson D, Hemrick-Luecke S, Threlkeld P, Heiligenstein J . Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002; 27(5):699-711. DOI: 10.1016/S0893-133X(02)00346-9. View

19.

DSouza D, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T . Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008; 33(10):2505-16. PMC: 3799954. DOI: 10.1038/sj.npp.1301643. View

20.

Trendelenburg U . The uptake and metabolism of 3H-catecholamines in rat cerebral cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1989; 339(3):293-7. DOI: 10.1007/BF00173580. View